A lack of clarity and final decision in the U.S. Food and Drug Administration's (FDA) recent letter to Iterum Therapeutics PLC (NASDAQ: ITRM) failed to deter H.C. Wainwright & Co’s bullish sentiment on Iterum stock.
Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to 4,348.47.
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to 4,340.12.
Following the market opening Friday, the Dow traded up 0.10% to 34,667.85 while the NASDAQ rose 0.40% to 14,580.23. The S&P also rose, gaining 0.30% to 4,332.94.
​​​​​Iterum Therapeutics plc (NASDAQ:ITRM) has received a letter from the FDA regarding the sulopenem etzadroxil/probenecid marketing application review for uncomplicated urinary…
Gainers
T.A.T. Technologies Ltd. (NASDAQ: TATT) shares rose 53.4% to $9.09 in pre-market trading after the company announced a new MRO partnership with Honeywell.